Skip to content

Immediate Impact

February 3, 2025

GH Research Announces Phase 2b Trial Results with GH001 in Treatment Resistant Depression

Background


GH Research PLC is a clinical-stage biopharmaceutical company developing novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).
Its lead product candidate, GH001, is formulated for 5-MeO-DMT administration via a proprietary inhalation approach.

The Details

  • This represents a significant advancement in the field of psychedelic research with implications for further development of molecules with fast, therapeutic action and sustained durability with re-treatment.
  • This study found greater than 50% remission rates without the need for concomitant psychotherapy which has been traditionally used in many psychedelic research studies and has significant implications both for GH Research and for future investments in rapid-acting antidepressants and other molecules with psychedelic properties.

The Source

The phase 2b double blind TRD study results GH001 (5-MeO-DMT) were impressive but in need of replication. MADRS improvement of -15.5 on Day 8 (p<0.0001). Remission rate of 57.5% for 40 patients on active medication at Day 8 as compared with 0% in the 40 placebo patients (p<0.0001). 77.8% of the OLE completers were in remission at the 6-month visit, with infrequent treatments. Patients who had remission on Day 8 after their first active treatment had a 91.7% remission rate at 6 months
This represents a significant advancement in the field of psychedelic research with implications for further development of molecules with fast, therapeutic action and sustained durability with re-treatment.
This study found greater than 50% remission rates without the need for concomitant psychotherapy which has been traditionally used in many psychedelic research studies and has significant implications both for GH Research and for future investments in rapid acting antidepressants and other molecules with psychedelic properties.

See Source
atlas-dynamic-background-05

 Discussion Replay 

Understanding the Neuroscience ACCUMIN Score™

 Breaking Down the Impact Scores 


The Neuroscience ACCUMIN Index Score leverages a multi-faceted ranking system to assess the scientific depth, molecular significance, and classification relevance of a given study or discussion.

 
The Science Score reflects the methodological rigor and empirical foundation of the content, ensuring alignment with established research standards. 
The Molecule Score evaluates molecular interactions, compound efficacy, and biochemical relevance within the scientific domain. 

home_hero_image (21)
home_hero_image (22)

The Class Score provides insight into categorical accuracy and contextual placement within broader scientific literature.


The Composite Score is a weighted synthesis of the individual impact scores, designed to offer a holistic assessment of scientific discussions and literature. By integrating methodological credibility, molecular insight, and classification precision, this score ensures a balanced evaluation of a source’s overall scientific contribution. Researchers rely on this metric to quantify reliability, compare studies, and navigate complex data landscapes effectively.

 

Related Resources .

 

Understanding Affective Switch in Bipolar I Disorder

Patients with bipolar I disorder (BP-1) may experience affective switch . .

Download

Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Psychiatry

Number needed to treat (NNT) and number needed to harm (NNH) are metrics that . . .

Download

Potential Pharmacological Impact on Dopamine and Serotonin Receptors

Dopamine and serotonin are known neurotransmitters in the brain . .

Download